A detailed history of Outlook Wealth Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Outlook Wealth Advisors, LLC holds 7,428 shares of HALO stock, worth $414,259. This represents 0.12% of its overall portfolio holdings.

Number of Shares
7,428
Holding current value
$414,259
% of portfolio
0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 14, 2025

BUY
$42.57 - $61.09 $316,209 - $453,776
7,428 New
7,428 $355,000
Q1 2023

Apr 18, 2023

BUY
$32.86 - $55.7 $393,465 - $666,951
11,974 New
11,974 $457,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.77B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Outlook Wealth Advisors, LLC Portfolio

Follow Outlook Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Outlook Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Outlook Wealth Advisors, LLC with notifications on news.